Bipolar Disorder Treatment Market Size Uplifts AI Innovations

The global market for bipolar disorder treatments was valued at USD 9.74 billion in 2025 and is projected to grow steadily to reach USD 15.67 billion by 2034, at an annual growth rate (CAGR) of 5.43%. This growth is mainly driven by the rising number of bipolar disorder cases, influenced by modern lifestyles and rapid urbanization. Government efforts to raise awareness and improve healthcare infrastructure are also playing a big role in boosting market expansion.

Get All the Details in Our Solutions – Request a Brochure: https://www.towardshealthcare.com/download-brochure/5473

Table of Contents

Snapshot of the Market (2023–2034)

Key Insights:

North America led the global market in 2024.
Asia-Pacific is expected to be the fastest-growing region during the forecast period.
Antipsychotics were the most widely used drug class in 2024.
Antidepressants are expected to grow the fastest in the coming years.
Hospital pharmacies accounted for the largest share in 2024.
Online pharmacies are projected to grow at the fastest rate in the future.

What’s Driving the Growth?

Bipolar disorder, also known as manic-depressive illness, affects mood, energy levels, and activity. It often results in extreme emotional highs (mania) and lows (depression). Both genetic and environmental factors contribute to the condition, and stress can often trigger episodes.

With changing lifestyles and increasing work pressure, cases of bipolar disorder are on the rise. Thankfully, growing awareness—driven by governments, healthcare bodies, and NGOs—is encouraging more people to seek help. Major investments in mental health research and treatment have also created a favorable environment for market growth.

For example, WHO’s Mental Health Gap Action Programme (mhGAP) operates in over 100 countries, helping improve access to mental health services, especially in developing nations.

Recent Trends & Developments

Bristol-Myers Squibb acquired Karuna Therapeutics in December 2023, strengthening its position in psychiatric treatments.
Eli Lilly is investing heavily in advanced bipolar disorder treatments and support programs.
In the U.S., about 2.8% of the population lives with bipolar disorder. The National Institute of Mental Health allocated $2.5 billion for mental health research in 2025.
China has introduced the Serious Mental Illness Management System (SMIMS) to support community care for severe mental illnesses, including bipolar disorder.

Latest Treatment Updates

BioXcel Therapeutics is enrolling patients in a Phase 3 trial for BXCL501, a dissolving film that treats acute agitation in bipolar patients.
Teva Pharmaceuticals and Medincell received FDA approval for UZEDY, an extended-release injectable for bipolar I disorder.
Autobahn Therapeutics launched a Phase 2 trial for ABX-002, a new adjunctive therapy for bipolar depression, with results expected in late 2025.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

How AI Is Shaping the Future of Bipolar Treatment

Artificial intelligence (AI) and machine learning (ML) are revolutionizing mental healthcare. These technologies can:

Help detect early signs of bipolar disorder using behavioral and genetic data.
Personalize treatment plans by predicting how a patient might respond to specific drugs.
Support drug discovery and accelerate clinical research.
Enable real-time monitoring of mood and symptoms through AI-powered wearables and apps.
Improve access to care through telemedicine platforms.

These innovations are making diagnosis faster, treatment more precise, and care more accessible.

Market Drivers, Challenges, and Opportunities

✔️ Key Growth Driver: Rising Bipolar Cases
Modern lifestyles, stress, and genetic factors are contributing to a steady increase in bipolar diagnoses, driving demand for effective and diverse treatment options.

⚠️ Key Challenge: Side Effects of Medications
Some commonly used medications, like lithium and Divalproex, can cause side effects such as nausea, weight gain, thyroid issues, and more. These side effects may discourage some patients from starting or continuing treatment.

💡 Key Opportunity: Technological Advancements
Tech like AI, mobile apps, and wearables is helping with early diagnosis and ongoing care. Telemedicine is expanding access to treatment, especially in remote areas. Innovative drug delivery systems are also making treatment more effective and personalized.

Example: Pear Therapeutics is adapting its digital therapy app reSET-O for bipolar disorder treatment to support patients alongside conventional drugs.

Market by Segment

🔹 Antipsychotics – Leading the Market
In 2024, antipsychotic drugs remained the most prescribed for bipolar disorder, especially for managing mania and mood swings. Long-acting injectables (LAIs) are helping improve patient adherence. Popular drugs include Seroquel, Olanzapine, and Aripiprazole.

Recent Update:
In April 2024, Vanda Pharmaceuticals received FDA approval for Fanapt, a new antipsychotic for treating acute manic episodes in bipolar patients.

🔹 Antidepressants – Fastest Growing
Antidepressants are gaining popularity for their effectiveness in treating depressive phases of bipolar disorder. They also come with fewer side effects, making them more appealing to many patients.

🔹 Hospital Pharmacies – Leading Distribution Channel
Hospital pharmacies accounted for the largest distribution share in 2024, driven by increased hospitalization rates for severe cases and access to specialist care.

To invest in our premium strategic solution and customized market report options, click here: https://www.towardshealthcare.com/price/5473

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Our Trusted Data Partners